Purpose Recent routine testing for liver function and anti-mitochondrial antibodies has increased the number of newly diagnosed patients with primary biliary cirrhosis (PBC). This study investigated the prognosis of asymptomatic PBC patients, focusing on age difference, to clarify its effect on the prognosis of PBC patients. Methods The study was a systematic cohort analysis of 308 consecutive patients diagnosed with asymptomatic PBC. We compared prognosis between the elderly (55 years or older at the time of diagnosis) and the young patients (\55 years). The mortality rate of the patients was also compared with that of an age-and gender-matched general population.
Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic disease characterized by progressive destruction of the small septal and interlobular bile ducts [1] [2] [3] . Chronic cholestasis may result in hepatic fibrosis and portal hypertension, which may eventually progress to hepatic failure or gastrointestinal bleeding. Thirty years ago, most patients diagnosed with PBC showed liver cirrhosis and disease-related symptoms [4] [5] [6] . The overall survival of PBC patients was 10-15 years, which was significantly less than that of age-and gender-matched controls from the general population [7] [8] [9] [10] .
Recent routine testing for liver function and anti-mitochondrial antibodies (AMAs) has increased the number of newly diagnosed cases of asymptomatic PBC [11] . There are several prognostic studies of these asymptomatic patients, suggesting that a significant proportion are in the early stage of PBC and might respond favorably to medication without further disease progression for several years [2, 11, 12] . Studies of the clinical significance of antinuclear antibodies (ANAs) in PBC have indicated that PBC-specific ANAs, such as Sp100, promyelocytic leukemia proteins, gp210, and p62 correlate with disease activity and may be markers of poor prognosis [13] . The only accepted index to estimate patient survival is the Mayo risk score, which is very useful in advanced cases; however, it is of limited use in patients with early disease [14] .
Recent studies on age differences in patients with autoimmune hepatitis (AIH) showed more frequent presentation of elderly patients with severe disease [15, 16] . However, the relationship between age at diagnosis and the prognosis of PBC patients remains unclear. The present study investigated the proposal that young and elderly asymptomatic PBC patients have different prognoses. To test this hypothesis, we compared clinical features, including prognosis, between the two age groups of patients. We also compared the mortality rates for PBC patients with those of an age-and gender-matched general population.
Patients and methods

Patients
This study was a systematic cohort analysis of 308 consecutive patients (271 females and 37 males) diagnosed with asymptomatic PBC at Okayama University and affiliated hospitals from 1980 to 2004. A diagnosis of PBC was made based on any two of the following criteria: [1] positive test for AMA, [2] biochemical evidence of cholestasis, and [3] liver biopsy compatible with the diagnosis [12] . The presence of AMA was determined by indirect immunofluorescence on murine tissue sections (cutoff value; 1:40) or enzyme-linked immunosorbent assay against beef pyruvate dehydrogenase. Pruritus, jaundice (bilirubin [ 2 mg/dl), bleeding varices, severe general fatigue, and ascites were defined as symptoms associated with disease progression. Patients showing serum positivity for hepatitis B surface antigen or anti-hepatitis C virus (HCV) antibodies, those with a daily ethanol intake of more than 60 g, and those with other signs of liver injury were excluded from this study. The study was carried out in accordance with the Helsinki Declaration, and was approved by the ethics committees of the relevant institutes. All patients provided informed consent.
Histological evaluation
Histological stages were evaluated according to the criteria of Ludwig et al. [1] . Briefly, stage I was defined as portal inflammation confined to the portal triads; stage II as portal and periportal inflammation without septal fibrosis or bridging necrosis; stage III as lobular fibrosis and/or bridging necrosis; and stage IV corresponded to cirrhosis.
Survival statistics
All patients were examined for physical status and the development of disease-related symptoms. Patients who had not visited our hospitals in the previous 6 months were contacted by letter or telephone and asked to provide details of recent medications and any disease-related symptoms, by using questionnaires. If they had visited other hospitals, we also asked them about the results of any endoscopy or imaging studies. For patients who had died, the date and cause of death were recorded. Only those patients followed for at least 1 year were included in the prognostic analysis. Survival statistics were compared between PBC patients and the general population (age-and gender-matched), using a standardized mortality ratio (SMR). The SMR was calculated by dividing the observed number of deaths by the expected number of deaths, as calculated from gender-and age (5-year)-ranked mortality in the Japanese general population in 2003, in Vital statistics in Japan published by the Statistics and Information Department of the Japan Ministry of Health and Welfare [17] . The 95% confidence intervals (CIs) for the SMR values were assumed to follow Poisson's distribution.
Statistical analysis
Data values are expressed as means ± SD or medians (ranges). Patient characteristics were compared among the groups by using the v 2 test, Mann-Whitney-U test, and Kruskal-Wallis test. The proportional hazards model was utilized to estimate the effects of patients' characteristics on survival. The survival rates and disease progression to symptomatic PBC were estimated by the Kaplan-Meier method, and compared using the log rank test. A P value of less than 0.05 was considered significant. Table 1 lists the clinical characteristics of the patients recruited in this study. The age of patients in this study showed a single peak in the fifties, with a median age at diagnosis of 56 years, which is in agreement with several previous studies [11, 18, 19] . Based on these results, the patients were divided into two groups: the young group (age \ 55 years) and the elderly group (C55 years). Most patients were female (88.3%). Interestingly, the male patients had a peak age distribution in the sixties (63 ± 11 years), which was significantly higher than that of the female patients (55 ± 11 years; P \ 0.01; MannWhitney U test). The frequencies of positive AMA and ANA showed no significant difference between the groups. The two groups showed similar values for alkaline phosphatase (ALP), but the young group had higher alanine aminotransferase (ALT) levels than the elderly (P = 0.03; Mann-Whitney U test). The elderly group had a significantly higher aspartate aminotransferase (AST)-to-platelet ratio and lower platelet count than the young group (P \ 0.01; Mann-Whitney U test).
Results
Patient characteristics
Survival of PBC patients
The survival of the PBC patients was evaluated with the data from 282 patients who were followed for at least 1 year. The mean period of follow up was 81 ± 50 months (86 ± 53 months in the young group and 77 ± 47 months in the elderly group). This period was defined as the time between diagnosis and either death or the latest confirmation of survival. The accumulated observation was 1904 person-years, accounting for 92.6% of the total potential follow up. The rate of disease progression to symptomatic PBC was significantly higher in the elderly group than in the young group (P = 0.023, log rank test; Fig. 1 ). At 10 years' follow up, 19% of the young and 35% of the elderly patients would have progressed to symptomatic PBC. Causes of death are summarized in Table 2 . Liver transplantation was considered a liver-related death when calculating the SMR. Twenty-four patients died or had a liver transplant. Liver failure and malignancies were the leading causes of death in both groups. Death in the young patients was most likely to have been due to liver failure (71%), while the elderly patients were more likely to have died from other causes before the occurrence of liver failure (88%; P \ 0.01; Fisher's exact probability test), especially from malignancies other than hepatocellular carcinoma (HCC; 35%). Two of the three patients who died of HCC were likely to have had advanced liver diseases, because they were in histological stage 3 at the time of diagnosis and the tumors were detected during an observation period of more than than 10 years. The annual incidence rate of HCC was 0.13%. Figure 2 shows that the overall survival rate was significantly lower in the elderly group than in the young group (P = 0.044; log rank test). At 10 years' follow up, 4.3% of the young and 16% of the elderly patients would have died. The results indicated that the elderly patients died from other causes before the occurrence of liver failure, and their survival rate was significantly lower than that of the young patients. We evaluated the effects of patients' characteristics on prognosis with the proportional hazards model (Table 3 ).
In the univariate analysis, old age, male gender, high Fig. 1 Disease progression rate to symptomatic primary biliary cirrhosis (PBC), stratified by age at diagnosis. The rates of disease progression to symptomatic PBC were estimated for both the young and elderly groups by the Kaplan-Meier method. The log rank test was used to compare the two rates. The rate of disease progression to a symptomatic state was significantly higher in the elderly group than the young group (P = 0.023; log rank test). At 10 years' follow up, 19% of the young and 35% of the elderly patients would have progressed to a symptomatic state Fig. 2 Overall survival rate of PBC patients, stratified by age at diagnosis. The survival rates of the young and elderly groups were compared by using the Kaplan-Meier method. The survival curves showed a significantly lower survival rate in the elderly group than in the young group (P = 0.044; log rank test). At 10 years' follow up, 4.3% of the young and 16% of the elderly patients would be dead AST-to-platelet ratio, and high ALP predicted short survival. The multivariate analysis, adjusted with the logistic likelihood ratio test, indicated that a high AST-to-platelet ratio, but not older age, was a significant predictive factor for short survival.
Comparison of PBC patients' mortality rate with that of age-and gender-matched general population Table 4 shows the overall mortality rate and the mortality rates for liver-related deaths, liver-unrelated deaths, and malignancies. The overall mortality rate of PBC patients was slightly higher than that of the matched general population (SMR, 1.6; 95% CI, 1.0-2.4). Importantly, the overall mortality rate of the elderly group was not different from that of the matched general population (SMR, 1.1; 95% CI, 0.6-1.7). Liver-related mortality was significantly higher among PBC patients (SMR, 47; 95% CI, 23-86), especially the young patients (SMR, 218; 95% CI, 71-509) than in the matched general population, while liver-unrelated mortality among PBC patients was not different from that in the matched general population (SMR, 1.0; 95% CI, 0.5-1.6). The mortality for malignancies among PBC patients was twice as high as expected (SMR, 2.3; 95% CI, 1.2-4.2), as shown in previous reports [20, 21] . These results indicated that the young patients were more likely to die from liver-related causes during the course of PBC, and that the elderly patients were just as likely to die from liver-unrelated causes, with survival expectancy similar to that of the age-and gender-matched general population. 
Discussion
Routine testing for liver function and AMA has increased the number of newly diagnosed cases of asymptomatic PBC, and several recent studies have attempted to clarify the prognosis of these asymptomatic patients, which has not been fully understood. The relationship between age at diagnosis and prognosis in PBC patients remains unclear. We hypothesized that age difference might have an important role in the prognosis of PBC patients, because age difference in disease progression has been reported in other chronic liver diseases such as chronic hepatitis C [22] and AIH [15] . The present study was a systematic cohort analysis of a large group of asymptomatic PBC patients, and the first to investigate the prognosis of PBC patients more precisely by dividing the patients according to their age at diagnosis. Considering the possibility of lead time bias, in that some of the elderly patients may have had delayed diagnosis of advanced stage PBC, we analyzed the correlation between age at diagnosis and the AST-to-platelet ratio, in order to estimate the effect of age difference on liver damage, and the correlation was not significant (R = 0.11; P = 0.065, canonical correlation analysis). There was no significant difference between the two groups in histological stage of liver biopsy specimens obtained at the time of diagnosis, with approximately half of them defined as stage 1. The age distribution of patients in the present study was similar to that in other multicenter studies [11, 18, 19] . These findings do not indicate that the elderly group may have involved patients who had a delayed diagnosis of PBC.
In regard to the mortality of asymptomatic PBC patients, there have been several conflicting reports. Prince and James [12] suggested that asymptomatic PBC patients have reduced survival compared with the general population, with an SMR more than 2.5-fold higher than expected deaths. Springer et al. [11] reported that asymptomatic PBC patients had shortened survival compared with a matched control population, and only the patients who remained asymptomatic survived as well as a matched control population. Uddenfeldt and Danielsson [23] showed that survival in asymptomatic patients was similar to that in the general population. In the present study, the mortality of PBC patients was slightly higher than that of the general population (SMR, 1.6; 95% CI, 1.0-2.4). Our analysis, by dividing the patients in the two groups according to their age at diagnosis, clarified that the elderly patients had an SMR similar to that of the general population (SMR, 1.1; 95% CI, 0.6-1.7), while the mortality rate of the young patients was seven times as high as expected. The influence of the age difference on mortality occurred partly because the mortality rate of the young general population was as low as 0.15% annually, which was one-twelfth of that of the elderly general population. The mortality rate of the young patients was much higher than that of the young general population, although it was significantly lower than that of the elderly patients or the elderly general population.
In the young patients in our study, deaths were likely to be from liver failure, or the patients were likely to receive a liver transplant, while the deaths of the elderly patients were more likely to be due to liver-unrelated causes such as malignancies. The elderly patients would be likely to develop disease-related symptoms if they lived long enough, but their survival might not be affected by the subsequent development of disease-related symptoms, because a considerable number of them died of liverunrelated causes before the occurrence of liver failure. These results indicated that death in the young patients would likely be due to liver-related causes during the course of PBC, and that the elderly patients were just as likely as the age-and gender-matched general population to die from liver-unrelated causes, with survival expectancies similar to those in the age-and gender-matched general population. Reports on cancer risk in PBC patients have suggested that there is a small increase in overall cancer incidence and mortality in these patients [20, 21] . Our results are consistent with these reports, showing that overall mortality for malignancies was higher than that in the general population (SMR, 2.3; 95% CI, 1.2-4.2). The mortality for malignancies was slightly higher that in the general population in both the young and the elderly groups, although this increase was not statistically significant. Except for HCC, it is unlikely that there is a high excess incidence of death for PBC patients from any cancer at a particular site. Periodical check-up for malignancies is necessary for the good management of PBC patients.
Many different drugs have been used to slow disease progression in PBC patients, with variable results. Ursodeoxycholic acid (UDCA) was reported to delay histological progression [24] [25] [26] [27] [28] [29] , and prolong survival without liver transplantation [30, 31] . However, these findings were challenged in two independent metaanalyses [32, 33] , showing that UDCA did not affect survival. Most patients in the present study (276 patients; 89%) were treated with UDCA over the course of the disease. There was no significant difference in use of drugs between the young and elderly groups (Table 1) . UDCA may be adequate as the initial treatment for elderly patients, because at least this agent does not reduce survival. On the other hand, young patients need active management to prevent liver failure, because our results indicated that they may develop disease-related symptoms at a relatively young age, and may not survive as well as the general population. Bezafibrate and immunosuppressants were additionally prescribed for 43 and 51 patients, respectively, in the present study. Our data were not sufficient to assess the survival benefits of these drugs.
In conclusion, age difference could be one of the important factors for predicting the prognosis of PBC patients, because our findings showed that the mortality rate of PBC patients aged 55 years or more diagnosed at the asymptomatic stage was not different from the mortality rate of the general population. The elderly patients may have more advanced disease than the young patients. Death in the young patients was more likely to be due to liver failure, while the elderly patients died from liverunrelated causes such as malignancies. Active management of liver disease may lead to a better prognosis in young PBC patients.
